B+
Bull case
28%
Probability
Target price
$11.50
+100.7% vs current
EOLS
EvolusANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
47%
Probability
Target price
$9.25
+61.4% vs current
B-
Bear case
25%
Probability
Target price
$5.25
-8.4% vs current
AI sentiment snapshot
Latest data as of 2026-06-26
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+99.8
Score
AI commentary
Primary-source tone remains moderately constructive because the latest substantive company update is the May 4, 2026 earnings release filed with the SEC, which showed revenue growth, a second straight quarter of positive adjusted EBITDA, reaffirmed 2026 guidance, and reiterated both the Estyme Europe launch and anticipated later-2026 Evolysse Sculpt approval [#SEC-8K-2026-05-04]. News flow since then has been supportive but not thesis-changing, and the June 12, 2026 8-K does not appear to add a meaningful operating reset [#8-K-2026-06-12]. The peer frame is improved by using direct aesthetics competitors for operating context, but clean public valuation comps remain limited, analyst-revision visibility is thin, and social coverage is absent in the packet, so the setup still reads as a cautious monitoring view rather than a broad re-rating call.
RankAlpha Sentiment Codex - 2026-06-26
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-08-10catalystQ1 profitability and 2026 outlook need to hold through the next earnings checkpointHigh impact
Evolus reported Q1 2026 net revenue of $73.1M, up 7% year over year, delivered a second consecutive quarter of positive adjusted EBITDA, and reaffirmed 2026 net revenue guidance of $327M-$337M with a low- to mid-single-digit adjusted EBITDA margin outlook [#SEC-8K-2026-05-04]. The next key test is whether Jeuveau growth, Evolysse momentum, and operating leverage remain intact into the next quarterly print.
2026-12-31eventEvolysse Sculpt U.S. approval remains the clearest discrete upside triggerHigh impact
Management said it continues to anticipate U.S. approval of Evolysse Sculpt later in 2026 while framing the injectable portfolio expansion as part of the growth plan [#SEC-8K-2026-05-04]. A timely approval would strengthen the portfolio-expansion narrative, while delay or a narrower-than-expected outcome would likely pressure sentiment.
2028-12-31catalystEuropean filler rollout and margin expansion must translate into durable cash generationHigh impact
Management tied the mid-May 2026 European Estyme launch, expense discipline, and portfolio scaling to a path toward positive 2026 adjusted EBITDA and 13% to 15% adjusted EBITDA margins in 2028, alongside greater capital-structure flexibility as free cash flow improves [#SEC-8K-2026-03-03] [#SEC-8K-2026-05-04]. That is a real operating roadmap, but still a monitoring catalyst rather than a confirmed financing or strategic transaction.
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-26 • Updated nightlySource: Internal modelMethodology